Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy

• References

• 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
• 2 Van Hinsbergh VW M, Kooistra T, Emeis JJ, Koolwijk P. Regulation of plasminogen activator production by endothelial cells: role in fibrinolysis and local proteolysis. Int J Radiat Biol 1991; 60: 261-272
• 3 Blasi F. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-111
• 4 Bachmann F. The plasminogen-plasmin enzyme system. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. J.B. Lippincott; Philadelphia: 1993: 1592-1622
• 5 Rijken DC, Wijngaards G, Welbergen I. Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 1981; 97: 477-486
• 6 Petersen TE, Martzen MR, Ichinose A, Davie EW. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990 265: 6104-6111
• 7 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
• 8 Plow EF, Felez J, Miles LA. Cellular regulation of fibrinolysis. Thromb Haemostas 1991; 66: 32-36
• 9 Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann NY Acad Sci 1992; 667: 52-63
• 10 Pennica D, Holmes WE, Kohr WJ, Haikins RN, Vehar GA, Ward CA Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli Nature 1983; 301: 214-221
• 11 Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL. Cloning and expression of the gene for pro-urokinase in Escherichia coli. Biotechnology 1985; 3: 923-929
• 12 Huber R, Carrell RW. Implications of the three-dimensional structure of a₁-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-8966
• 13 Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal foims of α²-plasmin inhibitor in human plasma. Biochem J 1993; 291: 623-625
• 14 Kimura S, Aoki N. Cross-linking site in fibrinogen for α₂-plasmin inhibitor. J Biol Chem 1986; 261: 15591-15595
• 15 Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence DA. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
• 16 Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Miiller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor-1 -binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461
• 17 Kruithof EK O, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of plasminogen activator inhibitor from the histiocytic lymphoma cellline U-937. J Biol Chem 1986; 261: 11207-11213
• 18 Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptorforurokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol J Biol Chem 1991; 266: 1926-1933
• 19 Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligandbinding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991; 266: 7842-7847
• 20 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin J Biol Chem 1982; 257: 2912-2919
• 21 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
• 22 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemostas 1989; 62: 1083-1087
• 23 Sobel BE, Nachowiak DA, Fry ET A, Bergmann SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysis. Coron Art Dis 1990; 1: 111-119
• 24 Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator. Ann Intern Med 1990; 112: 529-538
• 25 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction N Engl J Med 1993; 329: 1615-1622
• 26 The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990 336. 71-75
• 27 ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. A randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet. 1992 339. 753-770
• 28 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 1993; 329: 673-682
• 29 Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
• 30 Myocardial Infarction Triage and Intervention (MITI) Trial. A patent infarct related artery improves diastolic filling after thrombolytic therapy. Circulation 1992; 86: 1-455 (abstract 1813)
• 31 EMIP Experience. Time intervals for prehospital intervention in acute myocardial infarction. Circulation 1992; 86: 1-15 (abstract 57)
• 32 Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Foiycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19: 885-891
• 33 Collen D, Lijnen HR. Staphylokinase, afibrin-specificplasminogen activator with therapeutic potential. Blood 1994; 84: 680-686
• 34 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
• 35 Schlott B, Hartmann M, Giihrs KH, Birch-Hirschfeid E, Pohl HD, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology 1994; 12: 185-189
• 36 Schlott B, Hartmann M, Giihrs KH, Birch-Hirschfeid E, Gase A, Vettermann S, Collen D, Lijnen HR. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine 26. Biochim Biophys Acta 1994; 1204: 235-242
• 37 Collen D, Zhao ZA, Holvoet P, Marynen P. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992; 6: 226-231
• 38 Sobel BE. Coronaiy thrombolysis. Editorial overview. Coron Art Dis 1990; 1: 3-7
• 39 Runge MS. Prevention of thrombosis and rethrombosis. New approaches Circulation 1990; 82: 655-7
• 40 Gold HK. Conjunctive antithrombotic and thrombolytic therapy forcoronary-artery occlusion. N Engl J Med 1990; 323: 1483-1485